Clinical Trial Update: Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sacituzumab govitecan for locally advanced, recurrent, or metastatic cholangiocarcinoma is currently active but not recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING